Corporate Retrospective 2007: Daiso
Daiso Co. was founded in 1915 for the electrolytic production of caustic soda from seawater.
Daiso Co. was founded in 1915 for the electrolytic production of caustic soda from seawater. The company was set up in Osaka, Japan, and was called the Osaka Soda Company, Ltd.; the name was changed to the Daiso Co. Ltd. in 1988. The business of the Daiso Co. is centered on industrial chemicals that are of primary importance in various large manufacturing industries. Today, the company has 720 employees and overall revenue over ¥50 billion. With 250 international patents and about 450 in Japan, Daiso has a long-term commitment to product innovation. Daiso is one of the world's largest manufacturers of chromatographic-grade spherical silica gel and in order to expand its presence in North America, Daiso has recently set up a direct sales, marketing, and R&D operation for the preparative and process markets in Santa Clara, California.
Daiso provides fixed-bed flanged chromatography columns, slurry packing service, and bulk media.
With the United States focus on the demanding pharmaceutical market, Daiso's media must deliver consistent performance from analytical through prep to process in the development and commercialization of drug substances. For this purpose, a media was introduced in 2006 to specifically address peptide and protein purification. In addition, the company plans to introduce a series of preparative columns in 2007. Daiso's United States business model, based on vertical integration from media manufacturing through column packing to direct sales and marketing, will permit aggressive pricing for products and services.
Congratulations to LCGC North America on their 25th anniversary.
Dr. Franco Spoldi
Dr. Franco Spoldi
VP Business Development
DAISO Fine Chem USA, INC.
Santa Clara, CA
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.
